Disadvantage and the Experience of Treatment for Multidrug-Resistant Tuberculosis (MDR-TB)

Affiliations

¹ Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 N Broadway, Baltimore, MD 21205 USA.
² Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, Maryland 21205 USA.
³ Department of International Health, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, Maryland 21205 USA.
⁴ School of Epidemiology and Public Health, University of Ottawa, 600 Peter Morand, Ottawa ON K1G 5Z3 Canada.
⁵ Johns Hopkins Berman Institute of Bioethics; and Department of International Health, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, Maryland 21205 USA.

Holly A Taylor et al. SSM Qual Res Health. 2022 Dec.

. 2022 Dec:2:100042.

doi: 10.1016/j.ssmqr.2022.100042. Epub 2022 Jan 28.

¹ Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 N Broadway, Baltimore, MD 21205 USA.
² Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, Maryland 21205 USA.
³ Department of International Health, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, Maryland 21205 USA.
⁴ School of Epidemiology and Public Health, University of Ottawa, 600 Peter Morand, Ottawa ON K1G 5Z3 Canada.
⁵ Johns Hopkins Berman Institute of Bioethics; and Department of International Health, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, Maryland 21205 USA.

No abstract available

Conflict of interest statement

Declarations of Conflicts of Interest: None

1. Bailey TC, Merritt MW, Tediosi F. (2015) Investing in justice: ethics, evidence, and the eradication investment cases for lymphatic filariasis and onchocerciasis. American Journal of Public Health; 105(4):629–36. - PMC - PubMed
1. Bhering M, Sarubbi V, Kritski A, Barbosa Assumpção Souza F & Duarte R (2020). Multidrug-resistant tuberculosis in Portugal: patients’ perception of the challenges faced during treatment. Portuguese Journal of Public Health; 38: 62–70.
1. Bieh KL, Weigel R, & Smith H. (2017). Hospitalized care for MDR-TB in Port Harcourt, Nigeria: a qualitative study. BMC Infectious Diseases; 17(1):50. doi: 10.1186/s12879-016-2114-x. - DOI - PMC - PubMed
1. Borisov SE, Dheda K, Enwerem M, Leyet RR, D’Ambrosio L, Centis R, Sotgiu G, Tiberi S, Alffenaar JW, Maryandyshev A, Belilovski E. (2017) Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR-and XDR-TB: a multicentre study. European Respiratory Journal; 49(5):1700387. - PubMed
1. Burtscher D, Juul Bjertrup P, Vambe D, Dlamini V, Mmema N, Ngwenya S, Rusch B Kerschberger B (2021). ‘She is like my mother’: Community-based care of drug-resistant tuberculosis in rural Eswatini. Glob Public Health;16(6):911–923. doi: 10.1080/17441692.2020.1808039. - DOI - PubMed